The human ␤-globin gene locus is located on chromosome 11 and is composed of five ␤-like globin genes (5Ј-ε, G␥, A␥, ␦, and ␤-3Ј). All five genes are regulated in a tissue-and developmental stage-specific fashion. The ε-globin gene is expressed in primitive erythroid cells of the embryonic yolk sac, while the ␥-and ␤-globin genes are silent. During definitive erythropoiesis in the fetal liver, the two ␥-globin genes are activated concomitant with ε-globin gene silencing. In definitive erythroid cells of the bone marrow, the ␦-and ␤-globin genes are activated, while both the ε-and ␥-globin genes are silenced. The developmental process that regulates stage-and organspecific transitions from ε-to ␥-to ␤-globin gene transcription, referred to as hemoglobin switching (35) , is in part regulated by interactions between the locus control region (LCR) and the genes.
The expression profile of the human locus changes somewhat when the genes are examined in transgenic mice (TgM). The ε-and ␥-globin genes are both expressed in primitive erythroid cells of the yolk sac (at 9.5 days postcoitum [dpc]). Abundant ␤-and diminishing ␥-globin gene expression is observed in definitive erythroid cells of the fetal liver (ϳ14.5 dpc). The two ␥-globin genes are completely silenced in adult spleen definitive erythroid cells (13, 29) . Thus, in TgM the two human ␥-globin genes are regulated as primitive stage-specific genes. Since the mouse lacks a true fetal stage of erythropoiesis, and the two human ␥-globin genes share highest homology with the murine ␤h1 gene among the mouse ␤-like genes, and since ␤h1 is most abundantly expressed in the murine yolk sac, it was anticipated that the human ␥-globin genes were regulated as though they were embryonic genes in the mouse (17) .
Despite thousands of clinical and experimental observations (28, 35) , the molecular basis for ␤-globin gene switching is not yet fully understood. It is generally accepted in this field that hemoglobin switching is a consequence of the interplay between developmental stage-specific transcription factors, which interact both within the promoters of the various genes and the 5Ј LCR, as well as any alteration of the physical location of a gene within the locus. We and others have documented that the distance or gene order relative to the LCR is a fundamental determinant of which gene is selectively activated during the primitive stage of erythropoiesis (7, 16, 31, 39) . In the definitive stage, however, the ε-and ␥-globin genes are autonomously silenced (13, 29) , regardless of their placement within the locus, or even if their expression is examined as individual transcription units (6, 32) . It is therefore most probable that a sequence-specific transcription factor(s) (activators and/or repressors) regulates ε-and ␥-globin activation and repression through nearby cis elements in a gene autonomous manner, independently from the amplifying effects of the LCR.
Erythroid cell-specific transcription factor EKLF (erythroid Krüppel-like factor) has been proposed to be one such regulator. Analysis of human adult ␤-globin gene expression in eklf-null mutant mice has clearly shown that EKLF is indispensable for definitive stage ␤-globin transcriptional activation, but additionally that it is dispensable for ε-and ␥-globin activation (27, 44) , fulfilling one anticipated requirement for a definitive stage-specific activator. EKLF binds to the proximal CACCC element of, and activates, the ␤-globin gene promoter (24) , and a ␤-thalassemia point mutation that leads to the loss of EKLF binding and consequently results in a moderate reduction in ␤-globin transcript accumulation (10) is often found in the proximal CACCC element (21, 25, 26) . However, since CACCC elements are also found in the ε-and ␥-globin gene promoters, it becomes difficult to resolve why the eklf germ line mutation should most dramatically affect the adult gene. Although the CACCC element sequences of the ␤-like globins differ slightly, this difference alone cannot account for differential EKLF promoter-specific recruitment in vivo (1). Moreover, EKLF is transcribed during both primitive and definitive erythropoiesis (34) and is active during both stages (43) . It therefore seems likely that preferential activation of the ␤-globin gene in adult definitive erythroid cells is regulated by factors in addition to EKLF.
Primitive stage-specific human and mouse globin genes harbor binding sites for putative repressors that might interfere with EKLF recruitment to their promoter CACCC sites. In a search for such elements, we and others identified two copies of direct repeat (DR) elements in the human ε-globin promoter, while DR elements are absent from the adult ␤-globin gene promoter (11, 37, 41) . When we disrupted those sequences in human ␤-globin yeast artificial chromosome (YAC) transgenic mice (TgM), we found that the mutant ε-gene was activated (or failed to be repressed) during definitive erythropoiesis. Surprisingly, analysis of this ε-globin gene promoter mutant in a genetic background either containing or lacking EKLF demonstrated that EKLF is recruited to, and activates, the mutant promoter (41) . We then identified a unique DNA binding activity that bound to the ε-globin gene promoter DR sequences and named this protein complex DRED (direct repeat erythroid-definitive). Based on these observations, we proposed that DRED was a definitive erythroid stage-specific repressor whose activity suppressed ε-globin transcription by abrogating EKLF (activator) binding to the ε-globin CACCC sites. The ␥-globin genes, which are primitive and stage specific in the mouse, each also bear a single DR sequence element in their promoters, and we speculated that these DR elements are also involved in ␥-globin gene silencing in adult definitive erythroid cells (38) .
An alternative model for ␥-globin gene silencing was proposed by others (22) . They identified four tandem copies of CCTTG repeats within the proximal promoters of the two ␥-globin genes, and the same motif was also found in the ε-, but not in the ␤-globin, gene promoter. Reporter gene transfection and PIN*POINT analyses into mouse erythroleukemia (MEL) cells revealed that this motif suppressed ␥-globin transcription by interfering with the recruitment of EKLF to a neighboring CACCC site. Furthermore, an oligonucleotide containing four copies of the CCTTG motif formed a specific protein-DNA complex using nuclear extracts prepared from MEL cells.
In humans, expression of the ␥-globin genes is approximately 1% of the total ␤-like globin protein in adult erythrocytes. However, patients with hereditary persistence of fetal hemoglobin (HPFH) have increased basal levels of ␥-globin, comprising some 5 to 20% of total (35) . Among the score of well-characterized HPFH alleles, the Greek syndrome is the result of a point mutation in the A␥-globin proximal promoter (Ϫ117: G3A) (5, 14) . The two putative repressor elements discussed above (the DR and CCTTG motifs) overlap by two nucleotides, and the Greek HPFH point mutation could affect any factor binding to both elements (Fig. 1A) . Therefore, this mutation could elicit a phenotype in humans as a consequence of disrupting either the DR or CCTTG motif.
To clarify which sequence motif, either DR or CCTTG (or possibly both), function as the cis-element(s) responsible for adult erythroid ␥-globin gene silencing, we created two groups of point mutations: one that would solely disrupt the DR motif and another that would modify all four CCTTG repeat se- 
MATERIALS AND METHODS
EMSA. Electrophoretic mobility shift assay (EMSA) was performed as described previously (41) with only slight modifications. Nuclear extracts were prepared from MEL cells. Sequences of oligonucleotides used as probes or competitors are listed in Fig. 1B (only sense strands are shown). Doublestranded probe DNAs were end-labeled with [␥-
32 P]ATP, column-purified, and used for binding reactions. The binding buffer used was 11.1 mM Tris-HCl (pH 7.6), 55.5 mM NaCl, 1.1 mM EDTA, 2.2 mM MgCl 2 , 1.1 mM dithiothreitol, and 11% glycerol.
YAC mutagenesis and TgM. The targeting vector for mutating the DR motif in the human A␥-globin promoter was constructed as follows. PCR-directed mutagenesis was performed with the following oligonucleotides using the human ␤-globin YAC (A201F4.3 [39] ) as a template. Artificially introduced restriction enzyme sites are underlined and shown in parentheses: HAGP1-5S, 5Ј-CTGGA ATGACTGGATCCGAACAAGGC-3Ј (BamHI); HAGP5-3A, 5Ј-TTGCCTTG TCAAGGAGATTGGACAAGGC-3Ј; HAGP6-5S, 5Ј-CCTTGACAAGGCAA GCTTGACCAATAG-3Ј (HindIII); and HAGP2-3A, 5Ј-GTCCATGTCTAGA CAACCAGGAGCCTGTGA-3Ј (XbaI).
PCRs were first initiated with the HAGP1-5S/HAGP5-3A and HAGP6-5S/ HAGP2-3A primer sets, respectively. The PCR products from the first of synthesis were combined, and a second round of PCR was performed with the HAGP1-5S/HAGP2-3A primer set. The resultant mutant DNA fragment, corresponding to the human A␥-globin gene promoter (nucleotides [nt] 39143 to 39704; HUMHBB; GenBank), was then digested with BamHI and XbaI and subcloned into BamHI/XbaI-digested pRS306 yeast-targeting vector. The mutation was verified by DNA sequencing. The yeast targeting plasmid DNA was digested with MscI (at nucleotide position 39281) prior to transformation of yeast bearing the wild-type human ␤-globin YAC to initiate homologous recombination (3).
Essentially the same protocol was followed for mutating the four tandem copies of the ␥-globin CCTTG motifs. Oligonucleotides used for PCR-directed mutagenesis were the HAGP1-5S, HAGP2-3A (above) and the following two sequences: HAGP4-5S, 5Ј-TGACCAATAGCCTGCAGTCGGCAAACTTGA C-3Ј (PstI), and HAGP3-3A,5Ј-AGGCTATTGGTCACTGCTCGGCTGGCCA ACC-3Ј.
The targeting vector DNA was linearized with PflMI (at nucleotide position 39273) and used for targeted recombination of the wild-type human ␤-globin YAC. Generation and structural analysis of human ␤-globin YAC transgenic mice was performed as described earlier (41) .
Semiquantitative RT-PCR analysis. Total RNA from a minimum of two animals from each of the transgenic lines was extracted from the yolk sac (9.5 dpc), fetal liver (14.5 dpc), adult spleen (made anemic by phenylhydrazine injection; 1 month old), or peripheral blood (from nonanemic mice) using ISOGEN (Nippon Gene). First-strand cDNA was synthesized with Moloney murine reverse transcriptase (ReverTra Ace; TOYOBO) using 2.5 g of total RNA in a 20-l reaction volume. PCR was performed with 1 l of cDNA in a 10-l reaction volume (50 M each deoxynucleoside triphosphates, 50 ng of each gene-specific primer set, 0.2 units of Taq polymerase [Invitrogen], 0.5 Ci of [␣-
32 P]dCTP, 1ϫ PCR buffer [2.5 mM MgCl 2 ]) under the following conditions: 94°C for 30 s, 58°C for 1 min, and 72°C for 1 min. PCR cycles were as followed: 12 cycles for ␤/␣ and 21 cycles for ␥ (adult spleen); 12 cycles for ␤/␣ and 18 cycles for ␥ (fetal liver); 12 cycles for ␥/␣ and 18 cycles for ε (yolk sac). Parallel control reactions showed that these cycle numbers were within the exponential amplification range. A sample of each PCR was electrophoresed on 8% polyacrylamide gels, dried, and subjected to PhosphorImager (Typhoon, Amersham) quantification and autoradiography. The PCR primers used were previously described (3, 39).
RESULTS
A␥-globin promoter mutagenesis. As described in the introduction, two putative repressor elements have been proposed to regulate the human A␥-globin promoter from positions neighboring the CAAT box (Fig. 1A) . The single DR motif and one of the four tandem copies of CCTTG motifs overlap by two base pairs, including the nucleotide that is mutated in the Greek-type HPFH (A␥ Ϫ117: G3A) (5, 14) . In order to discriminate which element is responsible for the HPFH phenotype, we designed two human A␥-globin promoter mutations. In the first mutant, we changed four nucleotides within and around the DR motif, while all four CCTTG motifs were left unchanged (mutDR, Fig. 1B ). In the second mutant, nine nucleotide changes were introduced to alter all four CCTTG elements, leaving the single DR motif intact (mutCCTTG, Fig.  1B ). Nucleotide Ϫ117 that is mutated in the Greek HPFH was not altered in either of the mutants.
We previously showed that the DR motif in the ε-and ␥-globin promoters form a unique complex with a protein recovered from MEL cell nuclear extracts, and we designated that complex DRED (41) . On the basis of both biochemical and genetic evidence, we proposed that DRED might be the factor responsible for silencing of the ε-and ␥-globin genes in adult definitive stage erythroid cells. In order to determine if the DR mutation (mutDR) successfully disrupted DRED binding to the ␥-globin promoter, we conducted EMSA using MEL cell nuclear extracts (Fig. 1C) . Since we had demonstrated that DRED bound with high affinity to the wild-type ε-globin promoter fragment that contains two DR sequences (Epsi in Fig. 1B ) (41), we used the ε-globin promoter fragment as a probe and all other sequences as competitors in the EMSA reactions. Radiolabeled Epsi probe and increasing amounts of MEL cell nuclear extract formed the anticipated complex (labeled DRED in Fig. 1C ). This complex was disrupted by including unlabeled Epsi fragment in the reaction. Wild-type (WT) and mutCCTTG A␥ promoter fragments efficiently competed with the labeled probe for DRED binding, indicating that functional DRED binding sites are present in these oligonucleotides. In obvious contrast, the mutDR as well as the adult ␤-globin promoter (Beta) fragments failed to disrupt DRED complex formation. Since the Beta fragment does not bear any DR sites, we conclude that the mutDR promoter lost significant affinity for DRED, while the mutCCTTG oligonucleotide retains undiminished DRED binding activity.
Lee et al. reported detection of a binding activity to the CCTTG-repeat sequences in MEL cell nuclear extract using EMSA (22) . We therefore attempted to determine if the mutCCTTG sequence lost its affinity for a putative CCTTGbinding factor. Although we used an identical probe (WTX4) and the identical binding buffer as reported in the previous work (22) in attempting to reproduce those data, we were unable to detect a binding activity in MEL cell nuclear extracts (data not shown) under those or any modified binding conditions, the reasons for which are currently unresolved.
Generation of YAC transgenic mice. The two A␥-globin promoter mutations, mutDR and mutCCTTG, were introduced separately into a 150-kb human ␤-globin YAC (A201F4.3) (40) by homologous recombination in yeast ( Fig. 2A) DNA (data not shown). The YAC DNA was purified by standard procedures (3) and was injected into fertilized oocytes to generate transgenic mice. Tail DNA from offspring (F0) was screened by PCR using human ␤-globin gene-specific primers followed by detailed Southern blot analysis (Fig. 2B and data not shown) to confirm the integrity and organization of the integrated YAC transgenes.
To verify the integrity of the integrated YAC DNAs in the mouse genome, high-molecular-weight DNA was prepared from thymi embedded in agarose plugs followed by SfiI enzyme digestion, pulsed-field gel electrophoresis, and Southern blot hybridization (Fig. 2B) . DNA fragments from the LCR (HS4-3Ј), the ε-globin gene (E3I), the ␤-globin gene (B3O), and inside of the SfiI site in the YAC right vector arm (R arm) were used as probes; all four probes detected hybridization bands of the expected sizes (10 and 100 kb; Fig. 2B ), demonstrating that each TgM line bore intact, unfragmented copies of YAC transgene(s). We identified two independent transgenic lines for each mutant YAC construct (lines 74 and 75 for mutDR and lines 251 and 428 for mutCCTTG). Further end-fragment and copy number analyses (using a fragment from the endogenous angiotensinogen locus as an internal control) (4) revealed that lines 74 and 251 carried a single YAC, while the other two (lines 75 and 428) bore two tandemly repeated YAC copies (data not shown).
Expression of the mutDR YACs in definitive and primitive erythroid cells. Two animals (1 month old) from each line of wild-type (single-copy lines 31 and 60, equal to the 60-loxP [39, 42] ) or mutDR (single-copy line 74 and two-copy line 75) TgM were treated with phenylhydrazine. After five days, anemic spleen samples were collected for RNA extraction and semiquantitative RT-PCR analysis (Fig. 3A) . Human ␤-and ␥-globin gene expression was compared between wild-type and mutant TgM, where endogenous mouse ␣-globin gene expression was used as the internal control. ␥-Globin expression dramatically increased in the mutDR TgM compared with that in the wild-type control (Fig. 3A, top) , while ␤-globin gene expression did not differ significantly (Fig. 3A, bottom) . Essentially the same result was obtained with the RNA obtained from the peripheral blood of nonanemic TgM (Fig. 3B) .
Since two types of ␥-globin genes (G␥ and A␥) are present in the human locus and the ␥ gene-specific primer set simultaneously amplifies both gene products, we next determined which of the two ␥-globin genes are ectopically activated in the mutDR TgM. Since the G␥-and A␥-globin genes diverged from a common ancestral gene quite recently during molecular evolution, their sequences are very similar (8, 33) . However, polymorphisms in restriction enzyme recognition sites can be found, notably here that a PstI site present in the A␥-globin gene is absent from the G␥ gene (Fig. 3C) . Therefore, RT-PCR amplification of the ␥-globin, as well as endogenous ␣-globin, mRNA in the exponential amplification range followed by PstI digestion of the PCR products allowed a distinction between A␥-and G␥-globin transcripts (Fig. 3D) . Quantification of the bands shown in Fig. 3D after executing the discriminating PstI digests revealed that the expression of the A␥-globin gene in the mutDR TgM increased in comparison with the wild-type, while expression from the (unmodified) G␥-globin gene in mutDR TgM did not differ from wild-type (Fig. 3E) . Thus, the promoter mutDR disruption autonomously affects A␥-, but not G␥-, globin gene transcription.
We next analyzed ␤-like globin gene expression in fetal liver definitive erythroid cells of the same lines of TgM (14.5 dpc). Elevated expression (two-to approximately threefold, compared with the wild-type control) of ␥-globin transcript was also observed in mutDR TgM at this stage, while ␤-globin expression was not statistically affected (Fig. 4A) . We again separately analyzed the expression of each ␥-globin gene ( Fig.  4B and 4C ) and found that mutant A␥-globin gene expression increased by three-to fivefold in comparison with the wild-type control. Curiously, expression of the (wild-type) G␥-globin gene in the mutDR TgM was also significantly higher (twofold) than that in the wild-type ␤-globin YAC TgM, when singlecopy TgM lines were compared (lines 31, 60, and 74).
We finally analyzed the expression of the human ε-and ␥-globin genes in the yolk sac (9.5 dpc). No significant difference was observed in the expression of these genes between the wild-type (line 31 and 60) (42) and the mutDR TgM lines (Fig. 5) . These results clearly demonstrate that mutation of the DR motif in the A␥-globin gene promoter affected its expression only in the definitive stage of erythropoiesis, which is consistent with our hypothesis that the DR elements in the ε-and ␥-globin promoters are the target motifs for a definitive stage-specific repressor.
Expression of mutCCTTG YACs in definitive and primitive erythroid cells. Finally, we investigated the in vivo role of the CCTTG repeat motifs in ␥-globin gene silencing. In the adult spleen, the level of ␥-globin transcription was unaltered in the mutCCTTG TgM, while that in the mutDR TgM dramatically (Fig. 6, top) . Among the wild-type, mutDR, and mutCCTTG TgM, the level of adult ␤-globin transcript accumulation did not significantly differ (Fig. 6, bottom) . Moreover, the level of either ␥-globin gene in the mutCCTTG transgenic mice was unaltered (data not shown).
In the fetal liver, however, expression of the ␥-globin gene in mutCCTTG TgM was slightly but significantly elevated (1.5-fold) when compared to wild-type TgM (Fig. 7A, top) , and this phenotype was mostly attributable to mutant A␥-gene expression, which increased ca. twofold when compared to wild type ( Fig. 7B and C) . Adult ␤-globin transcript levels were invariant comparing wild-type and mutCCTTG TgM (Fig. 7A, bottom) . In the yolk sac of mutCCTTG TgM, the level of the ε-or the ␥-globin gene was unaffected when compared to wild-type TgM (Fig. 8 ). These results demonstrate that the CCTTG motif may represent a weak repressor element that is active only in fetal liver erythroid cells, but it cannot represent a major silencing element for A␥-globin in adult definitive erythroid cells.
DISCUSSION
Globin gene switching has long been a central model for analyzing the molecular events controlling the temporal regulation of tissue-specific gene expression. In spite of intensive studies, we do not yet completely understand how ␤-globin gene switching is controlled. Human ␤-globin locus TgM have been generated using large cosmid (36) , YAC (13, 29) , and bacterial artificial chromosome (18, 19) DNAs for analysis of this issue, since tissue-and developmental stage-specific globin gene switching can be properly achieved only by using these technically challenging experimental tools. The Greek-type FIG. 5 . Expression of human ␤-like globin genes in the yolk sac of mutDR TgM. Semiquantitative RT-PCR analysis of ␤-like globin gene expression. Total RNA was prepared from the yolk sac of two embryos (9.5 dpc) derived from the intercross of male transgenic and female wild-type animals. Samples were collected from two independent litters from each mutant line. Expression of human ε (hε)-and human ␥ (h␥)-globin compared to endogenous mouse ␣ (m␣)-globin genes was analyzed separately by semiquantitative RT-PCR. The signals for hε-globin at 18 cycles and h␥/m␣-globin at 12 cycles were quantified by PhosphorImager, and the ratios of hε/m␣ (top) and h␥/m␣ (bottom) were calculated (the mouse ␣ signal at 12 cycles was set at 100% and the values are normalized by transgene copy numbers). The average Ϯ standard deviation from at least three independent experiments was calculated and graphically depicted. Representative results are shown below each panel. HPFH mutation has been introduced into a human ␤-globin YAC and then examined in TgM (30) . In this model, human ␥-to ␤-globin gene switching was delayed in comparison with TgM bearing the wild-type locus. This result thus ensured the validity of an approach attempting to investigate the mechanisms that regulate switching in human ␤-globin YAC TgM. Two cis DNA motifs, the DR and CCTTG sequences, have been proposed as silencing elements for definitive stage-specific human embryonic and fetal globin gene repression (22, 41) . To complicate matters, these overlapping motifs in the A␥-globin promoter contain the nucleotide mutated in the Greek HPFH syndrome therefore obscuring which motif might be responsible for the HPFH phenotype. Hence, we evaluated the roles of these two putative silencing motifs in ␥-globin gene repression by generating separately mutated A␥-globin gene promoters in human ␤-globin YAC TgM.
RT-PCR analysis of YAC TgM bearing mutDR clearly demonstrated that this motif functions as a definitive stage-specific repressor cis-element and is required for ␥-globin gene silencing (Fig. 3, 4, and 5 ). In the adult spleen, A␥-globin mRNA levels were almost 10-fold higher in mutDR TgM in comparison to wild-type controls (Fig. 3E) , while G␥-as well as ␤-globin gene expression levels were not altered ( Fig. 3A and E) . One might presume that a significant increase in ␥-globin gene expression would lead to a reciprocal decrease in ␤-gene expression, since these genes compete for the LCR enhancer activity within the locus in the competition model. Even in human patients with HPFH, however, increased ␥-globin expression is approximately 5 to 20% of total ␤-like globin protein in adult erythrocytes (35) . Consistent with this clinical observation, TgM carrying a human ␤-globin YAC with the Greek-type HPFH mutation in the A␥-globin promoter displayed ϳ10% of ␥-globin expression (at day 17 after birth [30] ). Therefore, it is unlikely that the level of ␥-gene expression in our mutDR TgM exceeds 10% of total ␤-like globin expression in adult erythrocytes, which may not be enough to competitively suppress ␤-globin gene transcription.
Curiously, expression of the human G␥-globin gene in the mutDR TgM was slightly elevated in fetal liver erythroid cells (Fig. 4C ). Since this phenotype was observed in only one of the lines (single-copy TgM line 74), it may simply be a position effect difference between the lines. However, this phenotype could also be genuine, since a similar increase was not observed in yolk sac erythroid cells (line 74 in Fig. 5C ) and that "expression per copy" value tends to be lower in Tg lines bearing multiple transgene copies. If this is a meaningful phenotype, it must be attributable to the DR motif mutation in the A␥-globin promoter, since the remainder of the ␤-globin locus is otherwise unaltered. Since the human G␥-and A␥-globin genes are separated by approximately 5 kb, we feel that it is unlikely that transcription factors associated with the A␥-globin promoter directly influence G␥-globin transcription. Recently, an attractive model has been proposed for human ␤-globin gene switching (2, 9, 15) . According to this model, the ␤-globin locus is divided into three subdomains, including either the LCR, the ε-and ␥-globin genes, or the ␦-and ␤-globin genes, and the model postulates that the "open-closed" status of the subdomains is developmentally regulated (12, 20) . Since the G␥-and A␥-globin genes would be in the same subdomain, the phenotype in mutDR could be explained as follows: when A␥-globin expression is activated by factors recruited to the promoter region of this gene, the chromatin structure of the entire ε/␥ subdomain is in an "open" configuration, and thus the G␥-globin promoter region becomes more readily accessible to activating transcription factors.
In primitive erythroid cells, no significant difference in A␥ gene expression was observed when comparing wild-type and mutDR TgM. This was expected, since we hypothesized that the repressor that bound to the DR motif was likely to be definitive stage specific. In summary, the data shown here demonstrate that the DR motif in the A␥-globin gene promoter significantly contributes to the mechanism controlling globin gene switching.
We also examined the role of the CCTTG repeat motifs in A␥-globin transcriptional regulation. These analyses showed that ␥-globin transcription in mutCCTTG TgM was slightly elevated, and only during the fetal liver stage, in comparison to wild-type controls (Fig. 6, 7 , and 8), and further that this increase was mostly attributable to elevated A␥-globin transcript accumulation (Fig. 7B and C) . Since we were unable to detect a CCTTG-specific binding activity in MEL cell nuclear extracts, we were unable to confirm if this mutation completely disrupted the binding of any CCTTG-associated proteins (22) . To ascertain a loss of binding activity as best we could, we introduced point mutations into all four CCTTG motifs in the A␥-globin promoter by referring to the reported oligonucleotide (MUTX4) that showed no binding activity in the previous report (22) . Although these genetic results suggest that the CCTTG repeats might collectively function as weak fetal liver stage-specific silencer cis elements, their effects are neither as pronounced nor as specific as those exerted by the DR motif.
Alternatively, it is possible that the small increase in the ␥-globin gene expression in the fetal liver of mutCCTTG TgM may still be due to the effect on the DR motif and its inter- acting protein (presumably DRED), since these two motifs are in very close proximity (Fig. 1B) . A small change in affinity (of DRED) may not have been detected in gel shift assay (Fig. 1C ) in this case. There have been two protein complexes that are reported to bind to DR sequences in definitive erythroid cells. One is the stage-specifically expressed nuclear receptor COUP-TFII (11) , and the other is DRED (41); indeed, both factors displayed reduced affinity to the DR target sequence when a Greek-type HPFH point mutation was introduced (23, 38) . Thus, it is important to determine the stage-specific activity and binding affinity of these factors to the wild-type and mutant A␥-globin gene promoters in order to conclude which protein is participating in ␥-globin gene silencing. Furthermore, it is probably mandatory to also analyze EKLF recruitment to the wild-type versus mutant promoters in vivo to more clearly elaborate the molecular mechanisms controlling ␥-globin gene activation and silencing. Such experiments should be feasible once antibodies against DRED and EKLF become available.
The first molecularly characterized human hemoglobinopathy was sickle cell anemia (SCD). A single amino acid substitution in the ␤-globin polypeptide causes production of an abnormal hemoglobin (hemoglobin S; HbS), and condensation of these abnormal hemoglobins into long polymers result in a debilitating, life-threatening disease. Hemoglobin F (HbF), containing ␥-globin chains, is known to inhibit polymerization of HbS, and HPFH mutations increase the synthesis of HbF, thus ameliorating SCD phenotypes and severity. Therefore, increasing HbF in patients with SCD or ␤-thalassemia by therapeutic means could reduce disease severity (35) . In this study, we showed that the destruction of the DR motif in the A␥-globin gene promoter recapitulates the HPFH phenotype in mice and therefore we expect that the DR sequence, or proteins that bind to it, could serve as targets for future SCD therapeutic development.
